CytRx Announces the Presentation of Favorable Results from Novel Combination of Aldoxorubicin and Do
LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (NAS: CYTR) , a biopharmaceutical research and development company specializing in oncology, announced that preliminary results from a Phase 1b ...
Why Amarin Corporation, CytRx Corporation, and Aegerion Pharmaceuticals Could Be the Biggest Biotech
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, ...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is ...
ImmunityBio's QUILT 88 study is a randomized, three-cohort, open-label study that evaluates the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care ...
A Strategic Path Informed by Stockholder Input and Charted by Your Board Given the importance of this year's Annual Meeting, we want to take this opportunity to share additional detail about the Board ...
CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tum
Aldoxorubicin shows prolonged clinical activity in two clinical trial patients with small cell lung cancer who have failed other therapies Data show that aldoxorubicin demonstrates a significant ...
LOS ANGELES, Nov. 13, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today provided a business update and ...
CytRx Corporation has announced that it has contributed $15.0 million, net of expenses reimbursed to CytRx, to its majority-owned subsidiary RXi Pharmaceuticals Corporation (RXi) to satisfy RXi’s ...
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative ...
LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 ...
“Investors like yourselves are consistently being duped by people like Adam Feuerstein.” That’s Steve Kriegsman, chairman and CEO of CytRx (CYTR), telling a small group of angry shareholders on Friday ...
CytRx Corp. came to the rescue of cash-strapped Innovive Pharmaceuticals Inc. with an acquisition offer worth up to $25 million, with most of that coming from future sales milestones. That deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results